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Abstract
Introduction: Multiple sclerosis is a demyelinating disease of the central nervous system which can cause severe disability and has
profound effects on patients’ quality of life over several decades. Although there is no cure for the disease, recently developed disease-
modifying agents have modest effects on the impact of disease progression. There is therefore a need for a new, effective, and well-
tolerated treatment for multiple sclerosis and FTY720 (an orally administered immunomodulatory compound with a novel mechanism of
action) is one of a number of agents being evaluated for the treatment of this disease. 
Aims: The objective of this article is to assess the therapeutic potential for FTY720, now in phase II clinical trials, for the treatment of
multiple sclerosis through a review of the published evidence.
Emerging evidence: There is good evidence that FTY720 achieves immunomodulation as shown by a reversible redistribution of
peripheral blood lymphocytes after oral administration. Two meeting abstracts have been published showing results obtained with
FTY720 in a 12-month phase II clinical trial in patients with active relapsing multiple sclerosis. There is modest evidence that FTY720
significantly improves both patient-oriented (relapse rate) and disease-oriented outcomes (inflammatory disease activity). There is good
evidence that FTY720 is well tolerated.
Profile: Based on these early results from the clinical development program, FTY720 has the potential to be an effective disease-
modifying agent for the treatment of multiple sclerosis. Further results from ongoing multinational phase III studies are awaited.
Key words: evidence-based review, FTY720, immunomodulator, multiple sclerosis
Core emerging evidence summary for FTY720 in multiple sclerosis
Outcome measure Emerging evidence
Patient-oriented evidence 
Disease relapse rates Reduction in relapse rates and time to first relapse
Likelihood that patients will at least have longer intervals between relapses 
Convenient administration Daily oral dosing with or without food 
No dose alterations necessary with hepatic impairment 
Tolerability Well tolerated. No serious adverse events noted. Most common adverse event is asymptomatic, mild, and
transient reduction in heart rate 
No evidence of increased risk of infections associated with drug-related lymphocyte sequestration
Disease-oriented evidence
Disease progression determined by  Reduction of new and existing inflammatory lesions responsible for subclinical disease progression
magnetic resonance imaging
Immunomodulation Reversible lymphocyte sequestration, a characteristic of the mode of action of FTY720, is a convenient
surrogate marker of immunomodulation Scope, aims, and objectives
Multiple sclerosis is one of the most common chronic neurologic
diseases causing progressive disability in young adults. The life
expectancy of patients with multiple sclerosis is at least 25 years
following the first onset of symptoms and most patients will die
from unrelated causes. In recent years there has been great
progress in understanding the pathogenic mechanisms
associated with the disease and imaging techniques have been
developed to monitor the effects of treatment on neurologic
lesions. However, although recently developed disease-modifying
agents have improved the management of multiple sclerosis,
there is still no treatment that stops the development of disability.
FTY720 is a novel immunomodulatory compound in clinical
development for use in the prevention of organ rejection in
transplant patients and for multiple sclerosis. 
The objective of this review is to evaluate the evidence for the
potential of FTY720 as a treatment for multiple sclerosis. 
Methods
The English language medical literature was reviewed for relevant
articles on FTY720 for the treatment of multiple sclerosis. An initial
search of PubMed, BIOSIS, and EMBASE was conducted on June
13, 2005 using the search terms “FTY720 OR FTY720 AND multiple
sclerosis” for articles published between January 1993 and June
2005 (inclusive). In addition, relevant abstracts were identified from
the annual scientific sessions of the European Neurological Society,
the American Society for Neurochemistry, and the International
Society of Neuroimmunology, held during 2002 and 2005. The
online database, www.clinicaltrials.gov was searched for
information on ongoing phase II and phase III studies with FTY720
in multiple sclerosis. A hand search of reference lists in selected
publications was carried out to ensure that no relevant articles were
omitted. 
A total of 16 articles (14 full papers and two abstracts) was identified
from the initial search strategy after any animal, in-vitro, or other
nonrelevant publications were omitted (Table 1). All of the full papers
identified initially were excluded from the evidence evaluation. Only
one meeting abstract was included for analysis as it reported
pertinent clinical outcomes with FTY720. Following the initial search
strategy a further six full papers were identified from reference lists
in the excluded full publications for inclusion in the review of
evidence. The search strategy was also repeated on January 10,
2006 when one further relevant meeting abstract was identified and
included. Thus, a total of eight publications (six full papers and two
meeting abstracts) were included in the evidence base.
Disease overview
Signs and symptoms 
Multiple sclerosis is one of the most common neurologic diseases
affecting young adults. It is usually a disease with sporadic
episodes and is characterized as a variably progressive disorder
of the nervous system in which patchy degenerative inflammatory
changes occur within the brain and spinal cord (Compston &
Coles 2002). The symptoms of multiple sclerosis are diverse and
can include tremor, paralysis, loss of bladder or bowel control,
fatigue, pain, loss of cognitive function, disturbances in vision and
speech, emotional changes, and nystagmus. These symptoms
can have a profound effect on patients’ quality of life and can also
lead to significant reliance on their family, dependents, and carers. 
The severity and prognosis of multiple sclerosis can vary greatly.
In about a quarter of all patients the disease does not affect
activities of daily living. However, severe disability can affect
about 15% of patients within a relatively short period of time
(Compston & Coles 2002) and approximately half of all patients
will require a cane for walking short distances within about
15 years of first onset of the disease (Weinshenker 1994). Attacks
can occur randomly, with an initial incidence of about one per
year followed by a steady increase in subsequent years. 
Epidemiology 
The incidence of multiple sclerosis is estimated to be seven cases
per 100 000 per annum, and the prevalence is approximately
120 cases per 100 000. The lifetime risk of the disease is one in
400 (Compston & Coles 2002). There are about 2.5 million
individuals with multiple sclerosis in the world, and in the USA
alone there are about 350 000 affected patients (Lutton et al.
2004). Multiple sclerosis develops in twice as many women as
men and age at onset of the disease is usually 20–30 years. About
5% of all cases occur in patients under the age of 16 years. 
Etiologic, genetic, and environmental factors
The relationship between genetic and environmental factors in
determining the susceptibility of patients to develop multiple
sclerosis is complex and poorly understood. However, it is clear
that there is an uneven geographic distribution of the disease in
populations of northern European origin and an increased
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Category Number of records
Full papers Abstracts
Initial search 14 2
records excluded 14 1
records included 0 1
Additional studies identified 61
Level 1 clinical evidence 00
Level 2 clinical evidence 5 2
Level ≥3 clinical evidence 10
trials other than RCT 00
case reports 0 0
Economic evidence 00
Total records included 6 2
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review159
prevalence in geographically temperate areas (Dyment et al. 1997).
Thus it is a disease that predominantly affects northern Europeans. 
To date the major histocompatibility complex (MHC) is the only
area of the human genome with a clear association with the
disease. Results from three genomic searches imply that a
number of genes with interacting effects will ultimately be found;
however, to date no single genetic region has been identified with
a major influence on familial risk (Dyment et al. 1997). In addition,
attempts to implicate specific environmental agents as
responsible for the disease have been unsuccessful. Possible, but
as yet unsubstantiated, candidate agents include Chlamydia
pneumoniae and human herpes virus 6 (Compston & Coles 2002). 
Pathophysiology 
Multiple sclerosis is characterized by acute focal inflammatory
demyelination and the loss of axons with limited remyelination
(Noseworthy et al. 2000). This leads to the presence of
characteristic multifocal sclerotic plaques in the white matter of
the central nervous system. These lesions are particularly
common in the optic nerves, and white matter tracts of the
periventricular regions, brain stem, and spinal cord (Hafler 2004).
Typically T and B lymphocytes, macrophages, and antibodies can
be found at the site of white matter destruction. 
A number of fundamental questions remain regarding the
pathophysiology of multiple sclerosis. For example, what initiates
the inflammation and what is the antigenic target driving the
inflammation (Hafler 1999)? Possible triggers for the initial
inflammatory insult include an autoimmune response (initiated by
autoreactive T lymphocytes) or a structural alteration in the white
matter as a result of microbial infection. It has also been
hypothesized that multiple sclerosis is a spectrum of diseases
and that some are initiated by an autoimmune response and
others are induced by viral infections of the central nervous
system (Hafler 1999). It is unlikely that the antigenic target driving
the disease is due to a single antigen. The inflammatory process
initiated by T-cell recognition of one myelin protein epitope
subsequently leads to the activation of autoreactive T cells
recognizing other epitopes of the same protein. This “epitope
spreading” can lead to activation of T cells recognizing other
myelin proteins that may get degraded and be presented on the
MHC of local antigen-presenting cells (Hafler 1999). 
It is known that trauma does not induce multiple sclerosis, nor
does trauma activate a latent form of the disease or alter
symptoms in a patient with the disease. However, the risk of an
exacerbation in a patient with multiple sclerosis has been shown
to be associated with stressful life events (Mohr et al. 2004). As
yet, specific stressors cannot be linked to exacerbations and
patients themselves should not be led to believe that they bear
responsibility (through experiencing stress) for them. 
Diagnosis
The typical stimulus for patients to seek medical help is the first
acute attack. An accurate clinical history and a thorough
neurologic examination are crucial for the accurate diagnosis of
multiple sclerosis. At present there is no specific immunologic-
based test for the disease. Results from imaging investigations
should be used to support the clinical diagnosis and to rule out
other pathologies. In the absence of clinical evidence,
abnormalities detected by imaging are insufficient grounds for a
diagnosis (Miller et al. 1998). Annual magnetic resonance imaging
(MRI) scans are also recommended for the management of
ongoing multiple sclerosis to monitor disease progression and to
detect underlying pathology. 
MRI has both prognostic and diagnostic applications in multiple
sclerosis. It has a pivotal role in the diagnosis of the disease and
acts as a surrogate marker of drug efficacy in clinical trials. The
use of imaging technology has been important in demonstrating
that even during apparently stable periods between attacks the
disease is still very active (Miller et al. 1998). 
Classification and clinical course
At onset, multiple sclerosis can be categorized clinically as either
relapsing remitting multiple sclerosis (RRMS) or primary
progressive multiple sclerosis (PPMS). The most common form of
the disease is RRMS, which is observed in about 85% of all
patients (Fig. 1). RRMS is characterized by clearly defined disease
relapses with full recovery or with sequelae and residual deficit
upon recovery. On average about 1.5 attacks occur each year and
approximately 10 new lesions are detected annually on MRI scan
(Hafler 1999). Although RRMS is not classified as a progressive
form of multiple sclerosis, residual deficits may occur after each
exacerbation. At least half of all patients with RRMS will transition
to secondary progressive multiple sclerosis (SPMS). This subform
is characterized by disease progression with or without
occasional relapses, minor remissions, and periods of stability. In
contrast, PPMS is seen in far fewer patients (about 10%; Fig. 1).
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Fig. 1 | Classification, incidence, and examples of clinical
courses of subtypes of multiple sclerosis (adapted with
permission from Kieseier & Hartung 2003) 
Classification Type of incidence Schematic typical
at presentation of clinical course
Relapsing remitting ~85%
multiple sclerosis
(RRMS)
Secondary progressive ~50% of patients
multiple sclerosis with RRMS will
(SPMS) progress to this
subform
Primary progressive ~10%
multiple sclerosis
(PPMS)
Progressive relapsing ~5%
multiple sclerosis
(PRMS)FTY720 | emerging therapy review
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Poor prognosis Good prognosis 
Motor involvement, in particular disturbed coordination or balance Sensory or visual symptoms dominate
Onset of disease in older males Complete recovery from individual attacks
Frequent and prolonged relapses with incomplete recovery within 2 years of disease onset
Short interval between the initial episode and first relapse
Onset of progressive phase
Table 2 | Disease course characteristics associated with the prognosis of multiple sclerosis 
It is characterized from the outset by the absence of acute attacks
but demonstrates a worsening in disease severity. 
Progressive relapsing multiple sclerosis (PRMS) is the least
common form of the disease, affecting about 5% of patients.
From the outset it is progressive, with or without full recovery, and
progression is continuous between relapse periods. 
Schematic representations of the courses of these four forms of
multiple sclerosis are shown in Fig. 1. During a relapse, symptoms
can develop over hours to days, persist for several days or weeks,
and then gradually dissipate. 
Prognosis 
Patients with sensory or visual symptoms as the dominant feature,
particularly those who experience complete recovery from attacks,
generally have the best prognosis. This pattern is common in
younger women (Compston & Coles 2002). Prognosis is
particularly poor in males when disease onset occurs later in life,
and in patients with frequent and prolonged relapses (particularly
in the first 2 years) and in those with a short interval between the
initial attack and the first relapse (Noseworthy et al. 2000) (Table 2). 
Current therapy options
The aim of treatment of multiple sclerosis is to reduce the
frequency (and limit the lasting effects) of relapses, relieve
symptoms, prevent disability arising from disease progression or
incomplete recovery from relapses, and promote tissue repair
(Compston & Coles 2002). 
The management of multiple sclerosis has greatly benefited from
the availability of five disease-modifying agents which have been
approved by the US Food and Drug Administration (FDA) since
1993 and are now widely available. However, there is no cure for
the disease and available disease-modifying agents are lifelong
therapies. Other therapies may be used to alleviate some of the
chronic symptoms of the disease (spasticity, neuropathic pain,
and fatigue), but by their nature they do not alter the course of the
disease and there is a limited evidence base for symptomatic
drug treatment for symptom control (Thompson 2001). 
Disease-modifying agents 
Of the five disease-modifying therapies approved by the FDA for
the treatment of multiple sclerosis, four are immunomodulators
(three preparations of interferon beta and glatiramer acetate) and
one is an immunosuppressant (mitoxantrone). The disease-
modifying agents that are indicated for the treatment of RRMS
include the immunomodulatory agents interferon beta-1b for
subcutaneous administration (Betaseron®), two formulations of
interferon beta-1a for either subcutaneous (Rebif®) or
intramuscular administration (Avonex®), and glatiramer acetate
(Copaxone®). All four immunomodulators can be considered as
first-line treatments for RRMS (Goodin et al. 2002; NMSS 2005). 
Mitoxantrone (Novantrone®) is an inhibitor of the enzyme DNA
topoisomerase II which is responsible for uncoiling and repair of
DNA in both dividing and nondividing cells. Because of concerns
over cardiotoxicity this agent may only be used up to a cumulative
lifetime dose of ≥140 mg/m2 (equivalent to about 11 doses) (Anon.
2005b). It is administered intravenously and due to toxic adverse
effects it is generally reserved for the more progressive forms of
the disease. Thus it is indicated for the treatment of worsening
RRMS, SPMS, and PRMS. Recently, marketing of natalizumab (a
humanized alfa-4 integrin antagonist) has been suspended
because of reports of two serious adverse events (two cases of
progressive multifocal leukoencephalopathy, one proving fatal).
This agent had previously received accelerated approval in the
USA in November 2004 for reducing the frequency of
exacerbations in patients with RRMS after 1 year of treatment
(FDA 2005). 
The National Multiple Sclerosis Society (NMSS) has revised its
consensus guidelines on the use of disease-modifying agents
including interferon beta and glatiramer (NMSS 2005). The
recommendations specify the use of the following four
immunomodulators: interferon beta-1a (intramuscular), interferon
beta-1a (subcutaneous), interferon beta-1b, and glatiramer
acetate for all relapsing forms of multiple sclerosis and
consideration of their use for selected patients with a first attack
or who are at high risk of multiple sclerosis. Therefore, therapy is
appropriate in all relapsing patients, those with SPMS, PPRS, and
many patients experiencing a first attack, providing that no
contraindication exists. 
All of the agents approved for the treatment of RRMS have been
shown to reduce relapse rates in large-scale, randomized, double-
blind, placebo-controlled, prospective trials (reviewed in Goodin et
al. 2002). Both interferon beta-1a formulations have achieved
reductions in sustained disability progression in relapsing multiple
sclerosis when used during the early phase of the disease. For
example, positive results have been obtained from a number of
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separate 2-year placebo-controlled clinical trials involving patients
with RRMS treated with the three interferon beta agents. In
summary, interferon-beta treatment significantly reduced the
relapse rate by 30 to 37% compared with placebo treatment
(interferon beta-treated patient relapse rates ranged from 0.61 to
0.78 and placebo-treated rates from 0.9 to 1.2 relapses per year)
(Compston & Coles 2002). This change in relapse rate was also
associated with a reduction in the accumulation of disability with the
two interferon beta-1a (but not the interferon beta-1b) preparations. 
In RRMS glatiramer acetate, mitoxantrone, and azathioprine all
reduce relapse frequency and the accumulation of disability.
Glatiramer acetate is a random polypeptide composed of four
L-amino acids (glutamic acid, lysine, alanine, and tyrosine).
Results from a placebo-controlled study involving 251 patients
with RRMS showed that treatment with glatiramer acetate
significantly reduced the clinical attack rate over a 2-year period
by 27% (P=0.007 vs placebo) (reviewed in Goodin et al. 2002).
The indications for the use of glatiramer acetate are comparable
to those for interferon beta and it is appropriate to consider it for
treatment in any patient with RRMS (Goodin et al. 2002). For
those patients who fail to adequately respond to the disease-
modifying agents, the only therapeutic option is to consider
intensive immunosuppression with cytostatic agents or even
autologous stem cell transplantation (Kappos et al. 2004).
Disease-modifying agents that can be started and continued on a
long-term basis are referred to as “platform therapies.” Key
characteristics of an ideal agent used for platform therapy are
maximal efficacy, safety, tolerability, convenience, and low rates
of neutralizing antibody formation (neutralizing antibodies formed
in the body may block or neutralize the biologic effects of the
foreign protein or polypeptide, potentially decreasing the
therapeutic effects of these agents) (Stuart et al. 2004). During
periods of increased disease activity or instability other
treatments (e.g. corticosteroids and immunosuppressants) may
be used with platform therapy. Although almost all patients who
recover from relapses do so spontaneously to some degree, most
clinicians recommend treating a relapse if it has a significant
effect on function (Polman & Uitdehaag 2000). Corticosteroids
have been the first-choice agent for this role for a number of years
and although they shorten the duration of relapse and hasten
recovery it is unclear whether they affect the overall degree of
recovery or alter the course of the disease. 
In summary, disease-modifying agents have beneficial effects on
relapse rates, relapse-related disability, and MRI outcomes. These
effects are more pronounced early in the course of the disease,
are long lasting, and have no rebound effects (Kappos et al.
2004). Nevertheless these treatments are only partially effective;
they are administered parenterally and although they are generally
well tolerated there are some safety issues to be aware of (e.g.
potential cardiotoxicity with mitoxantrone). 
Unmet needs
One of the most important objectives of successful therapy for
multiple sclerosis is the prevention or postponement of long-
term disability. Typically, disability may evolve slowly over
many years; however, most clinical trials are conducted for
relatively short periods and only short-term outcome measures
(e.g. attack rates and MRI measures to establish that treatment
at least reduces the biologic activity of multiple sclerosis) are
used. Therefore, it is important that any short-term measure
is validated based on actual long-term patient outcomes
(e.g. reduction in disability). Indeed, there is some uncertainty
as to the relationship between the attack rate and long-term
disability. It has been suggested that reducing short-term
attack rate measures may not be associated with a delay in
the accrual of disability in multiple sclerosis (reviewed in
Goodin et al. 2002). 
Based on results from a number of large, well-designed clinical
trials it is generally accepted that interferon beta (1b or 1a) is the
treatment of choice for patients with RRMS (Polman & Uitdehaag
2000; Stuart 2004; Stuart et al. 2004). Nevertheless, there are still
some unresolved issues relating to its use including optimal
timing for the initiation and cessation of treatment; optimal dose,
frequency, and route of administration; long-term effects of
treatment; occurrence and relevance of neutralizing antibodies;
and cost (Polman & Uitdehaag 2000). In addition, up to 60% of
patients experience influenza-like symptoms (including fever,
chills, myalgia, and headache) with interferon beta (Calabresi
2004). The first-line choice for the treatment of SPMS is interferon
beta; mitoxantrone or cyclophosphamide may be considered as
second-line treatments for progressive disease. There are no
established therapies for either PPMS or PRMS (Kieseier &
Hartung 2003). 
Multiple sclerosis has a profound effect on patients’ quality of life
and it is important to determine the effect of any treatment on this
parameter. At present, no study has measured this as a specific
outcome of treatment. Instead, because the disease has been
shown to be modified by treatment (e.g. reduced relapse rates
and improvements in disability) this has led to the inference that
quality of life outcomes are likely to be improved by these agents
(NMSS 2005). However, this issue may be addressed through the
use of a suitably valid and reliable quality of life instrument
[e.g. the Multiple Sclerosis Impact Scale (MSIS29)]. 
Nevertheless, the management of multiple sclerosis has greatly
benefited from the development of new disease-modifying agents
such as interferon beta and glatiramer acetate as prior to their
introduction there were no effective therapies. But, despite their
widespread availability, they are still only partially effective (in
terms of reductions in relapse rates, relapse-related disability, and
imaging outcomes) in the treatment of multiple sclerosis, and all
the currently available disease-modifying agents must be
administered parenterally either by self-administration or under
medical supervision. In addition, there is no agent currently
available that is able to stop the disease process. Therefore,
characteristics of an ideal agent for the treatment of multiple
sclerosis would include oral administration (for convenience),
clinically significant effects on disease- and patient-oriented
outcomes, limitation of the disease process and reduced
disability, and good tolerability. 
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Much progress has been made on the immunopathogenesis of
the disease and many new promising therapeutic agents are
currently in development. In general, these agents can be broadly
categorized into either nonselective (antigen-nonspecific) or
selective (antigen-specific) therapies (Hohlfeld & Wekerle 2004).
FTY720 (Fig. 2) is a new nonselective therapeutic agent in
development for treatment of multiple sclerosis and will be
reviewed in detail below. It is a novel, orally active compound
derived from ISP-1 (myriocin), a fungal metabolite from Isaria
sinclairii that was a remedy for “eternal youth” in traditional
Chinese herbal medicine (Fujita et al. 1994). FTY720 is being
developed by Novartis Pharma AG in the areas of transplantation
and autoimmunity. 
Mode of action of FTY720
FTY720 elicits lymphocyte sequestration by facilitating a
reversible redistribution of lymphocytes from the circulation to
secondary lymphoid tissues. This is a unique immunomodulation
mechanism whereby T lymphocytes are effectively directed away
from inflammatory sites toward the lymphatic system. Because of
the structural similarity between FTY720 and sphingosine (a major
component of the sphingolipids found in mammalian cell
membranes; Fig. 2) it has been suggested that the drug may
interact with sphingosine receptors (Brinkmann et al. 2002).
Evidence suggests that FTY720 is phosphorylated in vivo via
sphingosine kinase to give FTY720-phosphate (FTY720-P) which
then participates in the sphingosine 1-phosphate (S1P) signaling
cascade (Brinkmann & Lynch 2002; Brinkmann et al. 2002). 
S1P stimulates multiple cell signaling pathways by interacting
with five (G-protein coupled) receptors, S1P1–5. Distribution of
these receptors shows that S1P1–3 receptors are widely
expressed whereas the S1P4 receptor is specific to lymphoid
tissue and S1P5 is found in the spleen and white matter tracts of
the central nervous system (Brinkmann & Lynch 2002). FTY720-P
interacts as a high-affinity agonist at four of the five S1P receptors
(S1P1 and S1P3–5) (Brinkmann et al. 2002).
Evidence of activity in animal models of multiple sclerosis
Orally administered FTY720 is effective in a number of preclinical
models of transplant rejection and autoimmune disease. The
experimental autoimmune encephalomyelitis (EAE) model is one
of the most widely used animal models of multiple sclerosis
mimicking a number of pathologic characteristics of the disease.
In a rat model, orally administered FTY720 0.3 mg/kg per day
prevented the development of EAE, as assessed by clinical
disease score (Brinkmann et al. 2002). In another study using a rat
model of EAE, oral FTY720 (0.3–1 mg/kg per day) completely
eradicated inflammatory lesions in the central nervous system, as
detected by either histology or MRI (Fujino et al. 2003; Rausch et
al. 2004). Furthermore, when compared with control-treated
animals in this study, FTY720 protected against both neurologic
impairment and inflammatory lesions during the acute phase of
the disease and subsequent first relapse (Rausch et al. 2004).
These encouraging results suggest that FTY720 may be a
promising candidate for clinical studies in the treatment of
multiple sclerosis. 
Outcomes achieved with FTY720 
Pharmacokinetic and pharmacodynamic outcomes following
single- or multiple-dose administration of FTY720 have been
determined in both healthy subjects and transplantation patients
(Table 3). These data are included here as these outcomes are not
affected by disease status and may be extrapolated to include
those patients with multiple sclerosis. 
Pharmacodynamic outcomes
Results from a number of clinical studies have shown that FTY720
produces profound and reversible immunomodulation following
oral administration. The mechanism of action of FTY720 leads to
a reversible redistribution of lymphocytes from the circulation to
secondary lymphatic tissue. The resulting lymphocyte
sequestration is a convenient surrogate marker of the
pharmacodynamic effect of FTY720 and may be a useful
parameter for monitoring the immunomodulatory effect of the
drug in the clinic. 
There is substantial evidence that lymphocyte sequestration
develops in healthy volunteers and renal transplant patients
treated with FTY720 (Table 3). Administration of a single oral dose
of FTY720 1 mg to 14 healthy volunteers resulted in a 38%
reduction in the number of peripheral blood lymphocytes 2 days
postdose (Kovarik et al. 2004b). In another study, the same dose
led to a 44% reduction in the number of blood lymphocytes in 32
subjects with or without hepatic impairment (Kovarik et al. 2005).
A similar effect was also seen in a phase I study after single-dose
administration of FTY720 (0.25–3.5 mg) to 20 stable renal
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Fig. 2 | Structure of FTY720 and related compounds (adapted
with permission from Brinkmann et al. 2002) 
 163
transplant patients receiving a cyclosporine-based regimen
(Budde et al. 2002). Although the higher doses of FTY720
produced a more rapid and sustained lymphocyte sequestration,
the actual degree of this property was similar across the range of
doses used in the study and no clear dose–response relationship
was detected. An analysis of the subsets of lymphocytes
sensitive to FTY720 was also performed in this study. The effect
of FTY720 was seen across all lymphocyte subsets except for
natural killer cells. As early as 4 h postdose, profound effects on
the different lymphocytes subsets were seen, with CD4+ and
naïve T-lymphocyte counts decreasing to the greatest extent
(Budde et al. 2003). 
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Level of  Outcomes FTY720 dosage  Study design and population Reference
evidence 
2 Drug exposure on d 7 was dose proportional for Cmax (5.0±1.0  1.25 (n=20) or 5 mg  Randomized, double-blind,  Kovarik et al. 
vs 18.2±4.1 ng/mL) and for AUC (109±24 vs 399±85 ng/h (n=20), or placebo  placebo-controlled,  2004a
per mL) for FTY720 1.25 and 5 mg/d, respectively  (n=20) once daily for  multiple-dose study
Peripheral blood lymphocyte counts decreased from baseline to 7 d in 60 healthy volunteers 
nadir (range 3–7 d after first dose) by 80 and by 88% in subjects  (age range 18–44 y)
receiving FTY720 1.25 and 5 mg, respectively. By d 35 lymphocyte 
counts recovered to within 75 and 50% of baseline values in the 
FTY 1.25 and 5 mg groups, respectively
2 Both Cmax (0.65±0.17 vs 0.64±0.18 ng/mL) and AUC (149±65 1 mg under fasting  Randomized, two-period, Kovarik et al. 
vs 139±43 ng/h per mL) were unchanged by the fasting  conditions or with  crossover, single-dose 2004b
or fed states, respectively a high-fat meal study in 14 healthy male
With both treatments the peripheral blood lymphocyte count  volunteers (age range 
decreased from baseline by 38±9% at 2 d postdose then  20–39 y)
increased towards predose values during the subsequent week
2 The absorption phase of FTY720 is prolonged, characterized by a 0.25 (n=6), 0.5 (n=6), Randomized, double-blind,  Budde et al.
tmax of >12 h  0.75 (n=3), 1 (n=3),  placebo-controlled, two-center, 2002;
Cmax (R2=0.966; P<0.001) and AUC (R2=0.916; P<0.001) were  2 (n=3), or 3.5 mg  single-dose study in 20 stable  Budde et al.
dose-proportional over the dose ranges (0.25–3.5 mg) (n=3), or placebo (n=8) renal transplant patients (mean    2003
All FTY720 groups showed a temporal pattern of relative lymphocyte 
age 43.2 y)
sequestration, seen at the latest 6 h postdose. No clear dose
response, but the highest doses showed a more pronounced  
reduction in lymphocyte numbers. Lymphocyte counts returned to 
~80% baseline values 24 h postdose
Almost all lymphocyte subgroups declined following FTY720  
treatment, with CD4+ and CD45RA+ cells being affected the most.
Natural killer cells, granulocytes, and monocytes were not influenced 
by FTY720 
2 Steady-state concentrations of FTY720 were achieved by w 4.   0.25 (n=4), 0.5 (n=4),  Randomized, multiple-dose,  Park et al. 
In the 10-fold dose range studied the pharmacokinetic profile of 1 (n=5), or 2.5 mg (n=5),  comparator study for 24 w (12-w  2005 
FTY720 was linear with dose (R2=0.679  and 0.982 for individual  vs MMF 2 g (n=5) treatment then 12-w follow-up).  
and mean FTY720 concentration, respectively) 23 renal transplant recipients  
CS doses and whole blood concentrations were unaffected  (mean age 40.1 y). All patients  
by FTY720 (or MMF). Therapeutic concentrations of CS were were treated with CS and PD
achieved in all groups during the study period, and required
no dose adjustment 
During 12-w treatment with FTY720 lymphocyte sequestration 
was seen as early as w 1, nadir was reached at w 4 and was fully 
reversed 4–8 w after cessation of treatment. The pharmacodynamics 
were not dose-linear over the 10-fold dose range (R2=0.57 and 0.53 
for lymphocyte sequestration vs drug dose and vs drug concentrations, 
respectively). Lymphocyte sequestration was not seen in the
MMF-treated group 
3 Cmax was not influenced by hepatic function (0.64±0.17, 1 mg Open-label, single-dose, case- Kovarik et al. 
0.65±0.12, 0.57±0.10 for controls, mild impairment, and controlled study in 16 subjects  2005
moderate impairment, respectively). Oral clearance was with mild (n=8) or moderate 
reduced on average by 10 and 31% for mild and moderate (n=8) hepatic impairment and 
hepatically impaired subjects compared with the respective 16 matched controls 
controls, reduced metabolism being the likely cause 
The magnitude of the pharmacokinetic changes suggests
that the FTY720 dose need not be adjusted in patients with
mild or moderate hepatic impairment
The effect on lymphocyte sequestration was similar across all
groups with a mean decrease of 44% from the predose baseline 
AUC, area under the concentration–time curve; Cmax, peak plasma concentration; CS, cyclosporine; d, day; h, hour; R2, correlation coefficient; tmax, time to Cmax; MMF, mycophenolate mofetil;
PD, prednisone; w, week; y, year.
Table 3 | Summary of pharmacodynamic and pharmacokinetic outcomes for FTY720 FTY720 | emerging therapy review
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The profound lymphocyte sequestration observed with multiple
doses of FTY720 has also been shown to be reversible after
cessation of drug treatment. For example, in a placebo-controlled
study lymphocyte counts decreased by 80 and 88% in healthy
subjects receiving orally administered FTY720 1.25 or 5 mg/day,
respectively (Kovarik et al. 2004a). The lymphocyte counts were
reduced at the first postdose sampling time point on day 2.
During the washout phase (between days 9 and 35) the
lymphocyte counts recovered towards baseline values. Similar
outcomes were also seen in a study with patients treated with
FTY720 0.25–2.5 mg/day for 12 weeks following renal
transplantation (Park et al. 2005). FTY720-induced lymphocyte
sequestration was observed during the first week of treatment
and the nadir was reached by week 4. This effect was fully
reversed 4–8 weeks after stopping treatment. 
Pharmacokinetic outcomes
The pharmacokinetic parameters of FTY720 are not influenced by
disease status and therefore these outcomes that have been
derived from studies in healthy volunteers and transplant
recipients are valid for patients with multiple sclerosis. 
Results from a number of phase I studies with FTY720 have
shown that the pharmacokinetic parameters following daily oral
administration are predictable and are not influenced by food
intake or impaired hepatic function (Table 3). Therefore, oral
administration of FTY720 is likely to be convenient and require
minimal dose adjustment when used in the clinic. 
There is substantial evidence to show that following oral
administration the absorption phase of FTY720 is prolonged,
characterized by a tmax of >12 h (Budde et al. 2002; Kovarik et al.
2004a,b, 2005). The pharmacokinetic parameters of FTY720 are
similar in healthy subjects and transplant recipients (Kovarik et al.
2004a). Hence pharmacokinetic data derived from healthy
subjects can be used to determine dosage guidelines for patients
(Kovarik et al. 2004a,b). Studies in healthy subjects have indicated
that FTY720 may be administered without regard to the timing of
meals and that no dosage alteration is necessary in patients with
mild or moderate hepatic impairment (Kovarik et al. 2004b, 2005).
Clinical outcomes
Thus far in its development for the treatment of multiple
sclerosis, only meeting abstracts covering one study have been
reported. This was a placebo-controlled study which showed
that orally administered FTY720 achieved promising patient-
and disease-oriented outcomes compared with placebo
treatment after 6 months, and continued with a subsequent
6-month extension. 
In this phase II international multicenter trial, 281 patients with active
relapsing multiple sclerosis were randomized to receive FTY720
1.25 mg (n=94), or 5 mg (n=94), or placebo (n=93) once daily for 6
months (Table 4; Kappos et al. 2005). The primary outcome was
inflammatory disease activity as assessed by the mean total
number of gadolinium (Gd)-enhancing lesions in monthly
postbaseline MRI scans. Compared with placebo, FTY720 1.25 and
5 mg/day significantly reduced inflammatory disease activity by 43
and 61%, respectively (P≤0.006). Similarly, new disease activity (as
measured by MRI) was also reduced by FTY720 (actual data not
provided). In addition, when compared with placebo treatment the
annual relapse rate was significantly  reduced by 55 and 53% with
FTY720 1.25 and 5 mg/day, respectively (P values not provided in
the abstract). A total of 86% of patients in both FTY720-treated
groups were relapse-free compared with 70% of placebo-treated
patients (P≤0.008) after 6 months. 
Level of  Outcomes FTY720 dosage  Study design and population Reference
evidence
2a Inflammatory disease activity (mean total number of Gd-enhancing 1.25 (n=94) and 5 mg  Randomized, multicenter,  Kappos et al. 
lesions in monthly postbaseline MRI scans) was significantly reduced (n=94) vs placebo (n=93) double-blind, placebo-controlled 2005
by 43 (P<0.001 vs placebo) and 61% (P=0.006 vs placebo) with 281 patients with active relapsing 
FTY720 1.25 and 5 mg, respectively. The annualized relapse rate was multiple sclerosis 
0.77 (placebo), 0.35 (FTY720 1.25 mg), and 0.36 (FTY720 5 mg) a
reduction of 55 and 53% with FTY720 1.25 and 5 mg, respectively,
vs placebo 
86% of FTY720-treated patients were relapse-free after 6 months
compared with 70% of placebo-treated patients (P=0.007 for
FTY720 1.25 mg, P=0.008 for FTY720 5 mg)
2a Annualized relapse rates reduced by >50% following switch from 1.25 (n=87) and 5 mg  250 patients in 6-month extension  O’Connor 
placebo to FTY720 (n=80), plus placebo to phaseb et al. 2005
For patients continually treated with FTY720 1.25 and 5 mg, 
1.25 mg (n=40), and  Patients switched from placebo 
80 and 83.8% were relapse-free, respectively
placebo to 5 mg (n=43) to FTY720 after 6 months
84.3 and 89.1% patients treated with FTY720 1.25 and 5 mg were
free from Gd-enhanced lesions at 12 months, respectively
aAbstract. 
bExtension of Kappos et al. 2005 study.
Gd, gadolinium; MRI, magnetic resonance imaging. 
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Level of Outcomes FTY720 dosage Study design and population Reference
evidence 
2 A total of 114 AEs reported by 36 subjects receiving FTY720 and 1.25 (n=20), or 5 mg  Randomized, double-blind,  Kovarik et al. 
placebo; 65 and 21% of the AEs were reported during the treatment (n=20), or placebo  placebo-controlled, multiple-dose 2004a
and washout phases, respectively. About half of the AEs consisted (n=20) once daily for study in 60 healthy volunteers
of headache (31%), dizziness (9%), and nausea (7%)  7 d (age range 18–44 y)
AE distribution was 16, 48, and 36% for FTY720 1.25 mg,
FTY720 5 mg, and placebo groups, respectively 
2 FTY720 preserved supine heart rate circadian rhythm. The heart rate 1 mg under fasting  Randomized, two-period,  Kovarik et al. 
vs time curve was shifted downwards by 10% over the first day conditions or with a  crossover study in 14 healthy  2004b
postdose, recovering to prestudy values after 3–5 d postdose. high-fat meal male volunteers (age range 
All changes were asymptomatic and unaffected by the fasting or 20–39 y)
fed states 
2 No serious AEs seen in the study. AEs occurred in 91% of 0.25 (n=6), 0.5 (n=6), Randomized, double-blind, placebo- Budde et al. 
FTY720-treated subjects vs 75% of placebo-treated subjects. Of 0.75 (n=3), 1 (n=3),  controlled, two-center, single-dose  2002
the 28 AEs reported the most common were transient asymptomatic 2 (n=3), or 3.5 mg  study in 20 stable renal 
reduction in heart rate (n=10) and headache (n=3), or placebo (n=8) transplant patients (mean age 43.2 y)
2a AEs were more frequently reported in the 5 mg group and the 1.25 (n=94) and 5 mg Randomized, multicenter, Kappos et al. 
most frequent events (>15% of patients) were mild headaches (n=94) vs placebo   double-blind, placebo-controlled  2005
and nasopharyngitis  (n=93) 281 patients with active relapsing
Treatment was well tolerated with 255 (91%) patients completing multiple sclerosis
the study and 89% elected to continue to the extension phase
3 15 AEs reported in 9 subjects; 12 AEs in 7 hepatic-impaired 1 mg  Open-label, single-dose, case- Kovarik et al. 
subjects vs 3 AEs in 2 control subjects. 6 AEs were suspected to controlled study in 16 subjects with  2005
be related to FTY720: somnolence (n=2), dizziness, (n=2), dry mouth, mild (n=8) or moderate (n=8) hepatic 
and nausea  impairment and 16 matched controls 
The effect on supine heart rate was similar across all groups with a
mean decrease of 13% from the predose rate occurring 2–4 h
postdose and recovering within 1–2 d
aAbstract.
AE, adverse event; d, day; h, hour; y, year.
Table 5 | Summary of outcomes associated with safety and tolerability achieved with FTY720 in clinical development
In the extension phase, patients continued on their blinded
FTY720 treatment while those assigned to placebo switched to
either dose of FTY720 (O’Connor et al. 2005). Results showed
that the annualized relapse rates were reduced by over 50%
following switch from placebo to FTY720. After 12 months’
treatment with FTY720 1.25 and 5.0 mg/day, 80.0 and 83.8% of
patients, respectively, remained relapse-free. In addition, MRI
assessments at 12 months showed that 84.3% in the
1.25 mg/day group and 89.1% in the 5.0 mg/day group were free
from Gd-enhanced lesions (Table 4). 
Safety and tolerability outcomes
There is good evidence that FTY720 is well tolerated in single-
and multiple-dose studies (Table 5). No serious adverse events
have been noted in any study. Reported adverse events that may
be treatment related include headache, dizziness, and nausea.
However, it is unclear from the reports as to what the incidences
of these events are following treatment with FTY720. 
Data from studies in healthy volunteers and transplant
recipients have been included as they provide drug-specific
outcomes that are relevant to all patients, irrespective of their
disease status. 
A commonly observed effect of FTY720 is a mild, asymptomatic,
transient reduction in heart rate which is not clinically relevant.
Supine heart rate shows a distinct circadian rhythm, which is
preserved following treatment with FTY720 (Kovarik et al. 2004b).
However, when compared with placebo, FTY720-associated
reduction in heart rate can be demonstrated by a downward shift
in the heart rate versus time curve by approximately 10% (Kovarik
et al. 2004b, 2005). This effect is consistent with agonist
properties on S1P receptors in the sinus node and atrial cells of
the heart and has been observed in preclinical models (Brinkmann
& Lynch 2002). The reduction in heart rate was reversible and
required no clinical intervention, and the effect was shown not to
be related to FTY720 blood concentrations (Budde et al. 2002). All
patients were asymptomatic, blood pressure remained within
normal limits, and no orthostatic reaction was seen in any patient. 
There is good evidence from the clinical studies thus far suggesting
that the lymphocyte sequestration seen following administration of
FTY720 for up to 6 months is not associated with the developmentof adverse effects. For example, no increased risk of infections has
been seen in renal transplant patients (Budde et al. 2002). 
The adverse events noted most frequently in the 12-month clinical
study in patients with relapsing multiple sclerosis were limited to
nasopharyngitis, influenza, and headache reported by >15% of
patients in at least one group treated with FTY720 (1.25 or
5 mg/day) (O’Connor et al. 2005). 
Resource utilization
Because FTY720 is still in the early stages of clinical development
no data has yet appeared indicating its value in resource
utilization. However, there are outcomes which may be measured
in future studies that will provide evidence for its utility in this area.
Such outcomes may include cost savings resulting from reduction
in long-term disability or reductions in the management of
adverse events. Reductions in relapse rates and frequency and
duration of attacks will also influence potential savings. 
The management of multiple sclerosis has benefited from the
development and availability of newer disease-modifying agents.
Nevertheless, although these newer therapies are able to improve
both patient-oriented (e.g. relapse rates and disability) and
disease-oriented (e.g. MRI-based data) outcomes their effects are
relatively modest. These treatments are also lifelong therapies.
Given that a patient may have the disease for several decades the
acquisition cost for these drugs alone will be substantial. There will
also be instances where the disease-modifying agents fail to be
effective in some patients. In these cases the therapeutic options
that may be considered include cytostatic agents to achieve
intensive immunosuppression and autologous stem cell
transplantation (Kappos et al. 2004). These options will also have
cost implications including costs associated with the management
of adverse events associated with immunosuppression and
processes surrounding transplantation.
All the current disease-modifying agents are administered by
injection, there being no conveniently administered oral agent
currently available. Mitoxantrone is administered intravenously
under medical supervision every 3 months and intramuscular
interferon beta-1a (Avonex) also requires medical guidance and
supervision for administration. Interferon beta-1a (Rebif),
interferon beta-1b (Betaseron), and glatiramer acetate may all be
self-administered subcutaneously but this requires medical
guidance initially. An effective orally administered preparation on
the other hand is likely to be more convenient for the patient and
reduce medical involvement. 
One of the most debilitating effects of multiple sclerosis is
long-term disability. This may impact significantly on patient
quality of life over many years and frequently requires
significant resources to support patients, their family, and/or
dependents. The Expanded Disability Status Scale (EDSS)
which ranges from 1 (least severe) to 10 (death from multiple
sclerosis) is a commonly used instrument for grading the
functional effects of multiple sclerosis and is the only
standardized testing element common to both clinical trials
and natural history studies. Cost studies in the UK have shown
that, on average, patients with less severe disease (EDSS
1–3.5) incur annual costs of around £3350 compared with
£9560 for those patients with more severe disease (EDSS
6.5–8.) (Richards et al. 2002). Therefore any treatment that can
effectively reduce the disability status of patients is likely to
have a considerable impact on quality of life and the economic
burden of the disease.
Patient group/population 
Thus far FTY720 has been evaluated in a 12-month trial in
patients with active RRMS and it is likely that further studies will
be conducted in patients with this form of the disease. One
reason for this is that RRMS is the most prevalent form of the
disease. Nevertheless it should be noted that as yet there are no
effective therapies for the least common types of multiple
sclerosis, PPMS, or PRMS. 
Drug profile 
Progress has been achieved in the treatment of multiple sclerosis
with the availability of newer disease-modifying agents. In
particular, these agents have shown some success in treating the
most common form of the disease, RRMS. However, there are a
number of limitations associated with the use of interferon beta,
glatiramer acetate, and mitoxantrone for treating multiple
sclerosis. For example, many patients treated with interferon beta
experience influenza-like symptoms, and although these may be
managed by pretreatment with nonsteroidal antiinflammatory
drugs, some patients may discontinue treatment. Also potential
cardiotoxicity associated with mitoxantrone restricts its use to the
treatment of the more aggressive forms of the disease without
exceeding the lifetime cumulative dose limit. Although disease-
modifying agents have shown efficacy, their impact on the course
of the disease is relatively modest. In addition, their acquisition
cost is high and parenteral administration can be inconvenient.
Less costly oral immunomodulatory agents are available (e.g.
azathioprine, cyclophosphamide), but they have less favorable
adverse-event profiles. In addition, there is no established
effective treatment for either PPMS or PRMS. Therefore, there is
the need for new, effective, and well-tolerated treatments,
particularly for oral administration, for multiple sclerosis. 
The novel S1P receptor agonist FTY720 is undergoing clinical
development for use in transplantation and autoimmunity. There
is substantial published evidence showing that FTY720 can
achieve reliable and reversible immunomodulation (lymphocyte
sequestration) following oral administration. In addition, 
there is good evidence that the pharmacodynamic and
pharmacokinetic profile of the drug is unaffected by the timing
of meals or hepatic impairment. 
FTY720 has shown promising results in preclinical models of EAE,
which in part has led to its clinical evaluation in multiple sclerosis.
There is moderate evidence from two meeting abstracts of a
phase II study that FTY720 (administered orally once daily for up
to 12 months) improved the patient-oriented outcomes of relapse
FTY720 | emerging therapy review
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rate and the likelihood of remaining relapse-free. In addition, there
is moderate evidence that disease-oriented outcomes were also
improved by FTY720 in that inflammatory disease activity (both
new and existing) was reduced as determined by MRI. 
Based on these early results of efficacy and tolerability from the
clinical development program, FTY720 has the potential to be an
effective disease-modifying agent for the treatment of RRMS. It
has the advantage over currently available treatments that it is
orally administered and has also exhibited a favorable tolerability
profile from the studies so far conducted. Further results from
ongoing multinational phase III studies are awaited. In particular,
data on its long-term effects on outcomes in the treatment of
RRMS (e.g. reductions in disability), utility for other forms of
multiple sclerosis, and tolerability will be anticipated. 
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